ArticleLife sciences2026
Endothelial cell LGR4 maintains liver sinusoidal endothelial cell Identity and protects against hepatic steatosis.
Article in Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsMetabolic dysfunction-associated steatotic liver disease (MASLD), the most prevalent chronic liver pathological condition, develops due to complex interactions among various hepatic cell types. Emerging evidence demonstrates the pivotal role of hepatic endothelium, specifically the liver sinusoidal endothelial cell (LSEC) phenotype, in MASLD pathogenesis. While global ablation of leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) improved metabolic fitness in mice, its cell-specific deletion revealed differential phenotypes. Here, we investigated the endothelial cell (EC)-specific role of Lgr4 in regulating LSEC phenotype and MASLD development. MATERIALS AND
methodsControl and EC-specific Lgr4 knockout mice were used. Mice were analyzed for metabolic parameters, LSEC phenotype, hepatic steatosis, and potential underlying mechanisms, following Western diet feeding. KEY
findingsMale EC Lgr4-deficient mice exhibited metabolic dysfunction as indicated by increased weight gain, fat mass, fasting blood glucose, and plasma triglycerides. Consistent with increased liver weight, male mice with EC Lgr4 deletion exhibited exacerbated hepatic steatosis and upregulated mRNA levels of scavenger receptors Cd36 and Olr1. However, no differences in fibrosis marker anti-smooth muscle actin were observed. Notably, immunostaining experiments demonstrated enhanced LSEC capillarization, evidenced by reduced LYVE-1 and increased EMCN expression in the livers of EC-restricted Lgr4 knockout mice compared with controls, which was accompanied by increased hepatic inflammation. Similarly, female EC-specific Lgr4-deficient mice had increased hepatic steatosis. Mechanistically, loss of EC Lgr4 in mice promoted expression of apoptotic markers and suppressed AMPK activation. SIGNIFICANCE: These findings identify EC Lgr4 as an important regulator of hepatic lipid metabolism, LSEC capillarization, and MASLD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.